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Purpose: The purpose of this study was to evaluate and compare medication adherence to 
chronic therapies in older populations across different regions in Europe.
Methods: This explorative study applied a harmonized method of data extraction and analysis 
from pharmacy claims databases of three European countries to compare medication adher-
ence at a cross-country level. Data were obtained for the period between January 1, 2010, 
and December 31, 2011. Patients (aged $65 years) who newly initiated to oral antidiabetics, 
antihyperlipidemics, or antiosteoporotics were identified and followed for over a 12-month 
period. Main outcome measures were medication adherence (medication possession ratio, 
[MPR]; implementation) and persistence on index treatment. All country-specific data sets 
were prepared by employing a common data input model. Outcome measures were calculated 
for each country and pooled using random effect models.
Results: In total, 39,186 new users were analyzed. In pooled data from the three countries, 
suboptimal implementation (MPR ,80%) was 52.45% (95% CI: 33.43–70.79) for antihy-
perlipidemics, 61.35% (95% CI: 52.83–69.22) for antiosteoporotics, and 30.33% (95% CI: 
25.53–35.60) for oral antidiabetics. Similarly, rates of non-persistence (discontinuation) were 
55.63% (95% CI: 35.24–74.29) for antihyperlipidemics, 60.24% (95% CI: 45.35–73.46) for 
antiosteoporotics, and 46.80% (95% CI: 36.40–57.4) for oral antidiabetics.
Conclusion: Medication adherence was suboptimal with .50% of older people non-adherent 
to antihyperlipidemics and antiosteoporotics in the three European cohorts. However, the degree 
of variability in adherence rates among the three countries was high. A harmonized method 
of data extraction and analysis across health-related database in Europe is useful to compare 
medication-taking behavior at a cross-country level.
Keywords: drug utilization, medication adherence, medication persistence, prescribing
Introduction
The treatment of chronic illnesses often includes the long-term use of pharmacotherapy, 
but although these medications are effective in treating chronic diseases, their full 
benefits are often not realized because ~50% of patients do not take their medications 
as prescribed.1 Recently, a European-funded consortium Ascertaining Barriers to Com-
pliance (ABC) project developed a Taxonomy of Adherence in an effort to standardize 
the medication-taking behavior terminology and measurement for clinical and research 
use. The taxonomy defines medication adherence “as the process by which patients 
take their medication as prescribed” and subdivides adherence into three essential 
elements, namely initiation, implementation, and discontinuation.2 Nonadherence to 
medications can thus occur in the following situations or combinations thereof: late or 
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noninitiation of the prescribed treatment, suboptimal imple-
mentation of the dosing regimen, or early discontinuation of 
the treatment (nonpersistence).
It is now well established that medication adherence is 
often poor, and this is perceived as a major public health prob-
lem in Western countries because it decreases the efficacy of 
pharmacological therapies, while at the same time increases 
direct and indirect related costs.3 For several reasons, poor 
adherence is more prevalent in specific groups of patients 
than in others. Older people experience greater morbidity 
with a corresponding increase in medication utilization 
and are at an increased risk of nonadherence.4 Medication 
adherence rates of 38%–57% have been reported in older 
populations with an average rate of ,45%.4 The European 
Community acknowledges the relevance of optimizing the 
prescribing processes as a mandatory element for commu-
nity health care systems to improve medication adherence 
in older adults.5 More specifically, this is the main aim of 
the action Group on Prescription and adherence to Medical 
Plans of the European Innovation Partnership on Active and 
Healthy Aging (EIP-AHA).6,7 Under the pillar of “prevention, 
screening, and early diagnosis,” the EIP on AHA identified 
“adherence to medication and medical plans” as a priority 
area in order to deliver tangible adherence approaches for 
patients in various disease areas, at the regional level and in 
different member states. As part of the collaborative work 
conducted in the group, partners identified the use of observa-
tional and large-population databases as a tool to investigate 
evidence on medication adherence in older populations and 
to facilitate data sharing.4,8
Pharmacy refill data provide an important, valid, and 
relatively efficient method of assessing retrospective medica-
tion adherence in large population-based research.4 However, 
few studies have undertaken cross-country comparisons of 
adherence. In general, drug-utilization studies have applied 
different methods of measurement of adherence across a 
range of different data sources and populations, making 
comparisons of the results of these studies difficult. On the 
other hand, using multiple data sources is not an easy task, as 
it implies a set of multiple actions to be taken, such as data 
and meta-data analysis, identification of common data sets, 
solving privacy and data property issues, and data integration.
The aims of this study were to 1) assess the feasibility 
of performing a collaborative cross-country comparison of 
medication adherence based on pooled outpatient dispensing 
data and 2) to compare medication adherence rates to three 
highly prevalent drug classes in older populations across 
three different European cohorts.
Methods
setting
This was an explorative study that applied a harmonized 
method of data extraction and analysis across health-related 
databases in Europe in order to compare medication adher-
ence at a cross-country level. The study was carried out on 
three health-related databases from three European countries 
(Republic of Ireland, Italy [Campania Region], and Spain 
[Aragon Region]).8
Access to health care is public in Italy and Spain, and drug 
policies are influenced by the central government. In Italy, 
drugs for the treatment of chronic conditions are fully covered 
by National Health Services with different levels of fixed 
or variable co-payment, depending on the drug category, 
patients’ income, chronic condition, and so on. In Spain, 
different levels of co-payment have been applied since 2012 
depending on patients’ income. The health care system in 
Ireland, which is predominantly tax-funded, operates as a 
two-tiered public and private system, with ~40% of the popu-
lation in receipt of public health insurance (General Medical 
Services [GMS] patients). The GMS scheme is mean-tested, 
with a higher income threshold for those aged $70 years, 
and provides individuals with free or substantially subsidized 
health care and prescription medications. It is estimated 
that over 75% of adults aged $65 years and ~92% of adults 
aged $70 years benefit from the scheme nationally and are 
subject to a flat co-payment for prescription medication 
(Table 1).9
Data sources
The three European electronic health care databases: the 
EpiChron Cohort in Aragon, Spain; the Health Services Exec-
utive Primary Care Reimbursement Services (HSE-PCRS), 
Ireland; and the Caserta Local Health Unit (LHU) from 
Campania Region, Italy; collect data on all drugs dispensed 
through the public health care system and have been shown 
to be valid for pharmacoepidemiological research.10–13 The 
characteristics of the databases have been described already 
by the Adherence Action Group partners, within the context 
of the EIP-AHA, with the aim to improve data sharing at a 
European level.8 Drugs were classified according to the World 
Health Organization Anatomical Therapeutic Chemical code/
Defined Daily Dose (ATC/DDD), which made between-coun-
try comparisons possible.14 As health-related databases rely 
on patient information records managed by National Health 
Services, all data stored in these databases can be considered 
population-based and a record of medications dispensed. 
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Adherence to chronic medication in older populations
using an anonymous patient code. Data were obtained for the 
period between January 1, 2010 and December 31, 2011.
Data extraction
The stepwise process adopted for the definition and harmoni-
zation of the queries for data extraction is shown in Figure 1. 
In order to facilitate the process of creating a common data 
structure and to identify a minimum common data set used 
by all three partners within the network, the investigators 
designed and completed “Data Definition Form (DDF).” The 
DDF described the information contained in the data sources 
used in the project. A common protocol was then developed 
and shared by partners to standardize definitions and study 
design, to reduce heterogeneity among individual studies, 
and to facilitate interpretation of the combined results. Data 
extraction and analysis scripts were implemented locally 
using statistical software packages in each database, and 
only outcome measure estimates were shared; each site 
wrote their own programs following a standardized protocol. 
Furthermore, in order to equalize the metrics of adherence 
evaluation, the researchers designed and filled out a “Metrics 
Definition Form (MDF)” describing all issues needing con-
sensus among partners.
study population and study drug 
categories
The study population in each country consisted of all people 
aged $65 years who had registered within the databases 
during the study period and who had at least 1 year of valid 
data (eligibility criterion).
The drug classes investigated in the study were anti-
hyperlipidemics (ATC C10A); oral antidiabetics (ATC 
A10B except A10BD); and antiosteoporotics (ATC M05B 
except M05BX). The excluded ATC categories refer to 
combination therapy; only monotherapy was included in the 
analysis. New users of the drugs in the ATC class of interest 
were identified between July 1 and December 31, 2010. The 
first date when the drug was dispensed was defined as the 
index date for each individual ATC drug class. A new user 
was defined as a patient not having any drug dispensed, of 
the same ATC class, over the 6 months period prior to the 
index date (wash-out period). Data for each patient were 
collected for a period of 1 year following the index date. 
Patients were classified into three treatment groups (per drug 
class). The treatment groups were not mutually exclusive, 
Table 1 characteristics of the health care systems of the three european countries
Characteristics Ireland Italy Spain
coverage of health care 
system
Predominantly tax-funded, operates 
as a two-tiered public and private 
system
Universal
in 2001, regional administrations 
acquired autonomy by the 
introduction of fiscal federalism
Universal
Physicians/100,000 inhabitants 292 410 375.6
Doctor visit/inhabitant/year Data not available Data not available 5.65
co-payment on drugs introduced in 2010. Depending on 
the category (i/ii according to the 
Primary Care Reimbursement Scheme)
reintroduced in 2001. 
Depending on patients’ income 
and on the Class classificationb
introduced in 2012. Depending 
on patients’ income and on the 
Class classificationb
Percentage of patients aged 
$65 yearsa
13.0 21.7 18.5
Notes: aeurosTAT 2015; bClass classification – patients who are exempt from paying co-payments because of low income, chronic illness, or old age.
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and patients could be prescribed all three classes of drugs. 
Patients’ age (in years) was assessed at the index date, and 
the patients were classified into the following age groups: 
65–74 years, 75–84 years, and .85 years.
Patients receiving combination therapy were excluded 
from the study as were patients who received only one pre-
scription of the drug class of interest (sporadic users) during 
the study period.
Days of drug supplied
To calculate the number of days of medication supplied for 
antiosteoporotics, we used the World Health Organization 
DDD methodology, which assumes one DDD as 1 day of 
therapy.14 For antihyperlipidemics and oral antidiabetics, we 
estimated the number of days or quantity of the drugs supplied 
per the number of pills based on previous research.15–17
Outcome measures
Definition
Medication adherence on the index treatment was evaluated 
according to the International Society for Pharmacoeco-
nomics and Outcomes Research definitions and as per the 
implementation phase and discontinuation (non-persistence) 
phase of the ABC taxonomy of medication adherence.2,18 
The implementation phase is defined as the extent to which 
a patient’s actual dosing corresponds to the prescribed 
dosing regimen, from initiation until the last dose taken. 
Persistence is the length of time between initiation and the 
last dose, which immediately precedes discontinuation. Non-
persistence was measured as the discontinuation phase, which 
marks the end of therapy where the next dose is omitted and 
further doses are not required.
implementation
Implementation was estimated by calculating the medication 
possession ratio (MPR) for each of the three drug classes in 
each country. MPR is a standard method of evaluating drug 
adherence and is defined as the number of prescribed therapy 
units divided by the number of assumed therapy units.18 It is 
calculated as the proportion of the number of days supplied 
over the intended period of treatment.
MPR was calculated by taking patients’ total days sup-
plied for each class of medication for the 365-day period 
following the index date and dividing by 365 (100×∑ (days 
supplied)/365). Patients should have filled at least two 
prescriptions of the drug class of interest in order to mea-
sure their MPR. MPR was expressed as a percentage and 
truncated to 100 when .100%, as per ESPACOMP recom-
mendations.18 It was calculated per user and per therapeutic 
subgroup. The threshold for adherence was set at 80% based 
on Haynes’ definition of adherence to antihypertensive 
medication; patients with MPR $80% were classified as 
adherent to treatment and those ,80% as nonadherent to 
treatment.19
Discontinuation (non-persistence)
Persistence was estimated by measuring the time gap 
between a dispensation of a drug and the next dispensa-
tion during the follow-up period of 1 year from the index 
date. All prescription fills/refills were for a 30-day supply. 
Patients were considered non-persistent if the gap between 
two refills was longer than 60 days (grace period), based on 
sensitivity analyses. Medication persistence was evaluated at 
the drug class level. Patients with at least one discontinuation 
episode were considered non-persistent. Switching products 
within index medication classes was not considered as an 
interruption.
Data synthesis
For each drug class, we calculated new users by age and 
gender in each country to account for differences in distribu-
tion among populations. The rates of nonadherence including 
implementation and discontinuation (non-persistence) 
were estimated, by age and gender, at the local level in 
each country. 95% CIs were obtained using the Clopper–
Pearson method. Pooled estimates were obtained using a 
meta-analytical approach treating each country as a different 
study. The random-effects model of DerSimonian and Laird 
was a priori selected due to the anticipated heterogeneity in 
nonadherence rates.20 Meta-analysis results were displayed 
using forest plots. The effect of gender and age was assessed 
by computing pooled OR with the relative 95% CI using a 
random effect model.
Statistical heterogeneity among countries was inves-
tigated using the I2 statistics.21 However, due to the small 
number of studies, no attempt was made to explore the causes 
of observed heterogeneity.
All analyses were performed with R statistics (version 
3.3.1), using the additional packages META e METAFOR. 
A p-value of ,0.05 was considered statistically significant.
ethics statement
For the Campania data, all procedures performed in this 
study were in accordance with the current national law 
from Italian Medicines Agency.51 The manuscript does not 
comprise clinical studies, and all the patients’ data were fully 
anonymized. For this type of study, formal consent is not 
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Adherence to chronic medication in older populations
study was granted by the responsible authority, Unità del 
Farmaco, Regione Campania.
For the EpiChron Cohort, the conformation of the 
EpiChron Cohort and data utilization for this study counts 
with the approval of the Clinical Research Ethics Committee 
of Aragon (CEICA – PI17/0024; PI16/088). Data contained 
in the EpiChron Cohort are not freely available. However, 
requests for collaborative work are welcome. Please contact 
the Principal Investigator by email (sprados.iacs@aragon.es) 
for further information.
For the HSE-PCRS data, patient consent is not required. 
Permission to use anonymized data for the present study 




The total population included 1,172,441 patients aged $65 
years. After applying selection criteria, 39,186 new users 
were considered for data analysis: 1) 2,639, 5,708, and 
16,798 new users in the antihyperlipidemic cohort for Italy, 
Spain, and Ireland, respectively; 2) 730, 1,837, and 4,482 
new users in the antiosteoporotic cohort for Italy, Spain, 
and Ireland, respectively; and 3) 1,226, 2,413, and 3,353 
new users in the oral antidiabetic cohort for Italy, Spain, 
and Ireland, respectively. Details on the number of patients 
excluded per the exclusion criteria are reported in Figure S1. 
Table 2 describes patient characteristics for each drug class 
across the three European cohorts. There were differences 
in the distribution of patients’ age across the three European 
cohorts, in the drug categories of interest. The Spanish cohort 
had a similar distribution between patients aged 65–74 years 
and patients aged 75–84 years (46.7 vs 43.0 and 42.2 vs 
43.8, respectively, in antiosteoporotic and oral antidiabetic 
medication use), while the Italian and Irish cohorts showed 
a higher percentage of patients aged 65–74 years than 
patients aged 75–84 years (53.7 vs 38.5 and 58.0 vs 28.9, 
respectively, in the antiosteoporotic category; 61.9 vs 32.1 
and 72.7 vs 21.0, respectively, in the antidiabetics category). 
All three countries had a higher percentage of new users aged 
65–74 years than new users aged 75–84 years for antihyper-
lipidemic medications (59.1 vs 34.6 Italian cohort; 50.9 vs 
39.4 Spanish cohort; 70.6 vs 22.7 Irish cohort). In particular, 
the Irish cohort had the highest percentage of new users aged 
65–74 years in all three classes of drugs.
implementation
The percentage of patients with suboptimal implementation 
of treatment, calculated as MPR ,80%, over a 12-month 
follow-up period was: 1) 34.68%, 55.69%, and 66.84%, 
respectively, for the Irish, Spanish, and Italian cohorts for 
antihyperlipidemic users; 2) 59.35%, 52.42%, and 71.78%, 
respectively, for the Irish, Spanish, and Italian cohorts for 
antiosteoporotic drug users; and 3) 27.47%, 27.60%, and 
36.62%, respectively, in the Irish, Spanish, and Italian 
cohorts for oral antidiabetic drugs users (Figure 2). 
The proportion of nonadherence (MPR ,80%) in the 
pooled data from the three countries was 52.45% (95% 
CI: 33.43–70.79, I 2 =99.9%, p,0.0001) for antihyper-
lipidemics, 61.35% (95% CI: 52.83–69.22, I 2 =97.5%, 
p,0.0001) for antiosteoporotics, and 30.33% (95% CI: 
25.53–35.60, I2 =95%, p,0.0001) for oral antidiabetics 
(Figure 2). In the pooled analysis, the odds of nonadherence 
(MPR ,80%), during 12-months, post-index period were 
significantly higher for patients aged $85 years than that 
of the comparison group (ie, patients aged 65–74 years) 
in the three drug categories (OR 1.43, 95% CI: 1.12–1.83 
for antihyperlipidemics; OR 1.41, 95% CI: 1.17–1.70 for 
antiosteoporotics; OR 1.63, 95% CI: 1.07–2.47 for oral 
antidiabetics); no difference was observed for gender 
(Table 3).
Details on nonadherence rates by age groups and by 
country are reported in Table S1.
Table 2 Demographic characteristics of new users for each drug 








number of new users 2,639 5,708 16,798
Age (in years), n (%)
65–74 1,560 (59.1) 2,905 (50.9) 11,853 (70.6)
75–84 914 (34.6) 2,248 (39.4) 3,812 (22.7)
$85 165 (6.3) 555 (9.7) 1,133 (6.7)
gender, n (%)
Female 1,546 (58.6) 3,420 (59.9) 9,196 (54.7)
Antiosteoporotics
number of new users 730 1,837 4,482
Age (in years), n (%)
65–74 392 (53.7) 858 (46.7) 2,601 (58.0)
75–84 281 (38.5) 789 (43.0) 1,295 (28.9)
$85 57 (7.8) 190 (10.3) 586 (13.1)
gender, n (%)
Female 673 (92.2) 1,622 (88.3) 3,820 (85.2)
Oral antidiabetics
number of new users 1,226 2,413 3,353
Age (in years), n (%)
65–74 759 (61.9) 1,019 (42.2) 2,439 (72.7)
75–84 394 (32.1) 1,057 (43.8) 703 (21.0)
$85 73 (6) 337 (14) 211 (6.3)
gender, n (%)
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As shown in Figure 2, at 1-year post-index, with the applica-
tion of a 60-day refill grace period, the proportion of treat-
ment discontinuation was 1) 36.87%, 60.93%, and 68.44%, 
respectively, in the Irish, Spanish, and Italian cohorts for 
antihyperlipidemic drug users; 2) 45.89%, 59.06%, and 
74.25%, respectively, in the Irish, Spanish, and Italian cohorts 
for antiosteoporotic drug users; and 3) 36.83%, 49.90%, and 
54.08%, respectively, in the Irish, Spanish, and Italian cohorts 
for oral antidiabetic drug users. The proportion of treatment 
discontinuation in the pooled data from the three countries 
was 55.63% (95% CI: 35.24–74.29, I2 =99.9%, p,0.0001) 
for antihyperlipidemics, 60.24% (95% CI: 45.35–73.46, 
I2 =99.2%, p,0.0001) for antiosteoporotics, and 46.80% 
(95% CI: 36.40–57.49, I 2 =98.7%, p,0.0001) for oral 
antidiabetics (Figure 2). In the pooled analysis, the odds of 
discontinuation during the 12-month post-index period were 
significantly higher for patients aged $85 years than for the 
comparison group (ie, patients aged 65–74 years) in the three 
drug categories (OR 1.36, 95% CI: 1.11–1.68 for antihyper-
lipidemics; OR 1.45 95% CI: 1.25–1.70 for antiosteoporotics; 
OR 1.50 95% CI: 1.26–1.78 for oral antidiabetics) (Table 3). 
Details on discontinuation rates by age groups and by country 
are reported in Table S2.
Discussion
Our analysis provides an overview of medication adher-
ence in older populations for three commonly used chronic 
medications across three European countries according to 
a common methodology. The drug classes examined were 
representative of chronic medications used to treat common 
and costly conditions in older populations. We found that 
in the first year of treatment, adherence to therapy was 
suboptimal with .50% of older people nonadherent to 
antihyperlipidemic and antiosteoporotic medication across 
the three countries. Almost a third of patients prescribed oral 
antidiabetic medication had suboptimal implementation of 
their medication regime and almost half were non-persistent. 
The implementation and discontinuation rates were not 
homogeneous among the three European countries. Italy 
had the highest percentage of suboptimal implementation 
and non-persistence across all three drug classes, and Ireland 
had the lowest. The extent of nonadherence to prescribed 
medications among patients affected by chronic diseases in 
Figure 2 Proportion of discontinuation (non-persistence) and proportion of nonadherence (MPr ,80%) in the pooled data from the three countries for (A) antihyperlipidemics, 
(B) antiosteoporotics, and (C) oral antidiabetics.
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Adherence to chronic medication in older populations
Italy has previously been reported as 70% while in Ireland 
31% of older people have been reported as nonadherent.22–24 
In Spain, the nonadherence rate ranges from 36% in the 
general type 2 diabetic population16 to 51% in patients aged 
over 65 years on multiple medications.25
Previous studies and comparability of 
major findings
To our knowledge, the present study is the first study to 
measure adherence to a range of chronic medications in older 
populations across European countries. As discussed above, 
previous European studies assessing adherence to therapy in 
older populations have been country/region specific and/or 
have focused on a single drug class or disease.26–33 Similar 
rates of nonadherence across the three drug classes have 
been reported in some US studies. A retrospective analysis 
of nonadherence in new users of six chronic medication 
classes, in a nationally representative pharmacy claims 
database representing one hundred US health care plans, 
found nonadherence rates of 39% in statins, 40% in bispho-
sphonates, and 28% in oral antidiabetics.32–34 Another US 
study, which compared retrospective drug adherence rates 
among patients with seven different medical conditions, 
reported nonadherence rates of 34.6% in type 2 diabetes, 
39.2% in hypercholesterolemia, and 49.8% in osteoporosis, 
which are lower than that reported in the current study.35 
In addition to a high level of nonadherence within the three 
countries, there was also a wide variation between the coun-
tries. Interestingly, a multi-country study based on data from 
the European Social Survey, which measured self-reported 
adherence to patients’ most recently prescribed medication 
(any medication), showed a relatively high level of adher-
ence (82%) across all countries, but there was substantial 
variation between European countries.36 The high level of 
self-reported adherence may be in reference to acute medi-
cation, where adherence has been shown to be higher than 
chronic medication.3,37
Within our multi-country study, the large differences 
in adherence across countries could not be explained by 
sociodemographic and socioeconomic variables alone, and 
further research is required to establish the reason behind 
these differences. An analysis of systematic reviews of 
determinants of patient adherence found that medication 
nonadherence is affected by multiple determinants, including 
social factors (eg, social support, economic factors), health 
care-related factors (eg, barriers to health care), condition-
related factors, therapy-related factors, and patient-related 
factors (eg, demographic, health beliefs).38 The variation in 
adherence in the current study may be explained by a range 
of such factors including differences in the structure of the 
health care systems and health insurance systems and dif-
ferences in disease prevalence and comorbidities. In Italy, 
after 2001, many regions decided to re-introduce both fixed 
and variable user charges on drugs using their increased 
autonomy in order to include the growth of public expendi-
ture, which could have negatively influenced adherence to 
therapy.39 A retrospective study investigating the effect of 
co-payments on adherence to chronic therapies among Ital-
ian regions showed a negative effect of co-payments on drug 
compliance, especially in regions with poor health care man-
agement, organization, and financing such as Campania.40,41 
Differences in chronic care programs in individual coun-
tries may also impact adherence. The Italian health system 
does not provide pharmaceutical care services for chronic 
patients, while in Ireland, the national clinical care program 
for diabetes may support older patients in adhering to their 
treatment, and in Spain, pharmaceutical care services are 
provided for chronic patients.42 The variation between the 
three countries may also reflect cultural differences in patient 
attitudes or beliefs toward medication taking. Furthermore, 
Table 3 Odds of discontinuation (non-persistence) and nonad-










Female 14,162 reference reference
Male 10,983 1.32 (0.52–3.36) 0.86 (0.77–0.95)
Age (in years), n
65–74 16,318 reference reference
75–84 6,974 1.06 (1.00–1.13) 1.13 (0.98–1.31)
$85 1,853 1.36 (1.11–1.68) 1.43 (1.12–1.83)
Antiosteoporotics
gender, n
Female 6,115 reference reference
Male 934 1.23 (1.02–1.49) 1.38 (1.03–1.86)
Age (in years), n
65–74 3,851 reference reference
75–84 2,365 1.06 (0.95–1.17) 1.16 (1.04–1.29)
$85 833 1.45 (1.25–1.70) 1.41 (1.17–1.70)
Oral antidiabetics
gender, n
Female 3,406 reference reference
Male 3,586 0.98 (0.89–1.08) 0.96 (0.86–1.06)
Age (in years), n
65–74 4,271 reference reference
75–84 2,154 0.98 (0.77–1.24) 1.08 (0.94–1.25)
$85 621 1.50 (1.26–1.78) 1.63 (1.07–2.47)
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the country heterogeneity of nonadherence to medication 
may depend on more general factors such as how effectively 
national health care systems address aspects of prevention 
and health literacy. A systematic review of barriers to medi-
cation adherence in older populations in the US found that 
lack of disease-related knowledge and health literacy were 
associated with nonadherence.43,46
Adherence was lower in the older age groups ($85 years) 
across all three countries. These findings are inconsistent with 
previous research which has shown that adherence increases 
with age.36 Increasing age has been shown to be a significant 
predictor of increased adherence to statins, antihypertensives, 
and antidiabetics.44,45 However, adherence to these medica-
tion classes has been shown to increase with age only up to 
a certain point, with those aged ,75 years likely to be more 
adherent than older patients.44,45 Older age is associated 
with increased morbidity, frailty, and cognitive impairment, 
which can result in decreased adherence and augmented 
discontinuation among older adults.47 Polypharmacy, which 
is also more prevalent in older populations, has been shown 
to decrease adherence.48
Multi-country database studies
A high value of combining diverse health-related databases 
for drug utilization research is the ability to evaluate medi-
cation adherence by applying the same criteria in terms of 
both data selection and analysis to all the databases involved. 
This represents an enhancement compared with classic 
meta-analysis because it helps in reducing biases in data 
extraction and management. Database networks present 
an opportunity for a better understanding of medication 
adherence and health care management across countries that 
differ in terms of their health care policies and the ability 
to compare and evaluate the impact of health care policies 
on patient behaviors and health outcomes. Future research 
could adopt a similar methodology to investigate the clinical 
implications of chronic disease nonadherence in older popu-
lations across countries and estimate the impact on health 
service use and cost. The authors faced two main challenges 
during this study: the first one was in relation to the setup of 
the shared data model, with the aim to be comprehensive, in 
terms of the information gathered from the partners, while 
also ensuring that the data were comparable. The second 
challenge was in monitoring the partners to ensure that they 
were following the same analysis protocol. Both these goals 
were achieved through an intensive exchange of information 
sharing among the partners, and one recommendation for 
future similar studies is to establish strong communication 
among partners and clear documentation of processes and 
checklists.
strengths and limitations
Although the methodology described in this work may 
not technically be defined as a meta-analysis, it neverthe-
less has permitted work on harmonized data that share the 
same methodology, thus avoiding ethical issues related 
to privacy of data. Being an explorative study, the crite-
ria used for the analysis were intentionally simplified to 
facilitate achieving consensus among the partners. Indeed, 
we investigated only adherence to monotherapy excluding 
more complex patterns of treatment. To have a uniform 
methodology, we defined a core data set, which lacked 
information on clinical data, comorbidities, complications, 
and side effects, which could have influenced our results. 
The database employed included population cohorts in 
Italy and Spain and older patients with a medical card in 
Ireland. Nevertheless these databases have been widely used 
in pharmaco-epidemiological studies at a national level to 
inform health care policy.
This study used MPR as a measure of suboptimal imple-
mentation and thus may have overestimated adherence as 
patients may not have taken all medications dispensed. 
Furthermore, although MPR ,80% cutoff is widely used in 
adherence research, it is an arbitrary number, and whether 
it is clinically important or not depends on many different 
factors and may be different for different drug classes.
For the assessment of persistence, patients with at least 
one discontinuation episode were considered nonpersistent. 
However, an intrinsic limitation of retrospective database 
analyses, such as this one, is that we are unable to track the 
reason for the discontinuation, for example, whether discon-
tinuation was recommended by the clinician (eg, a temporary 
suspension due to an adverse reaction). It should also be noted 
that pharmacy refill records only provide details on whether 
or not the patients were dispensed their medication and do 
not provide details on whether or not the patients actually 
ingested their medications.
A further limitation includes the limited availability 
of data at the time of the study (from 2010 to 2011). The 
limited number of countries involved in the analysis also 
did not allow us to perform a meta-regression to explore the 
source of high heterogeneity found in the pooled analysis. 
Nonetheless, the use of comprehensive pharmacy record data 
across the three countries provides an important estimate of 
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Adherence to chronic medication in older populations
This study also applied a rigorous taxonomy of adherence 
and methodology, and the results clearly demonstrate that it 
would be feasible to utilize these databases at a cross-country 
level as a tool to compare and evaluate medication-taking 
behavior.
implications of nonadherence
Poor adherence to medication has been estimated to 
cost ~€125 billion annually to European governments, 
contributing to an estimated 125,000 deaths each year, and 
accounts for approximately one-quarter of all admissions 
to nursing facilities and 10% of hospital admissions.1 It is 
evident that nonadherence in older populations is a global 
public health issue and interventions to improve medication-
taking behavior need to be informed by comparative adher-
ence studies which estimate the magnitude of nonadherence 
across both countries and chronic conditions.49,50
Conclusion
This study found variable but uniformly suboptimal medi-
cation adherence across three chronic medications in three 
European cohorts. The proportion of nonadherent older 
people was lower in Ireland (northern European country) 
than in Italy and Spain (southern European countries). 
This provides background information for studies aimed at 
investigating the factors responsible for these phenomena 
and for the development of initiatives to improve medica-
tion management in older populations in Europe. Common 
standards for data management in cross-country studies are 
not established. However, the results of this study provide 
a valuable proof-of-concept and pave the way for further 
research in order to identify optimal strategies for cross-
country management of medication adherence data.
Acknowledgments
The authors wish to thank the A1 Action Group members on 
Prescription and Adherence to Medical Plans of the European 
Innovation Partnership on Active and Healthy Ageing for 
their contributions. Editorial assistance was provided by 
Dr Melanie Gatt (PhD), an independent medical writer, on 
behalf of Springer Health care Communications. This was 
funded by the University of Naples Federico II, Naples, Italy.
Author contributions
All authors contributed toward data analysis, drafting and 
revising the paper and agree to be accountable for all aspects 
of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. World Health Organization. Adherence to Long-Term Therapies. 
Evidence for Action; 2003. Available from: http://www.who.int/
chp/knowledge/publications/adherence_full_report.pdf. Accessed 
November 10, 2017.
 2. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describ-
ing and defining adherence to medications. Br J Clin Pharmacol. 
2012;73(5):691–705.
 3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 
2005;353(5):487–497.
 4. Giardini A, Martin MT, Cahir C, et al. Toward appropriate criteria 
in medication adherence assessment in older persons: position paper. 
Aging Clin Exp Res. 2016;28(3):371–381.
 5. Costa E, Giardini A, Savin M, et al. Interventional tools to improve 
medication adherence: review of literature. Patient Prefer Adherence. 
2015;9:1303–1314.
 6. European Innovation Partnership on Active and Healthy Ageing. A1 
Action group 2016-2018. Version 9th February 2016. Template for 
the renovation of the existing Action Plans. Available from: https://
ec.europa.eu/eip/ageing/sites/eipaha/files/library/renovated_action_
plan_2016-2018_ag_a1_0.pdf. Accessed November 10, 2017.
 7. Illario M, Vollenbroek-Hutten M, Molloy DW, Menditto E, Iaccarino G, 
Eklund P. Active and healthy ageing and independent living. J Aging 
Res. 2015;2015:542183.
 8. Menditto E, Bolufer De Gea A, Cahir C, et al. Scaling up health knowl-
edge at European level requires sharing integrated data: an approach 
for collection of database specification. Clinicoecon Outcomes Res. 
2016;8:253–265.
 9. Department of Public Expenditure and Reform. General Medical 
Services Scheme; 2016. Available from: http://www.budget.gov.ie/
Budgets/2017/Documents/3.%20General%20Medical%20Services%20
Scheme.pdf. Accessed November 10, 2017.
 10. Orlando V, Guerriero F, Putignano D, et al. Prescription patterns of 
antidiabetic treatment in the elderly. Results from Southern Italy. Curr 
Diabetes Rev. 2015;12(2):100–106.
 11. Comella P, Franco L, Casaretti R, et al. Emerging role of capecitabine 
in gastric cancer. Pharmacotherapy. 2009;29(3):318–330.
 12. Grimes T, Fitzsimons M, Galvin M, Delaney T. Relative accuracy 
and availability of an Irish National Database of dispensed medication 
as a source of medication history information: observational study 
and retrospective record analysis. J Clin Pharm Ther. 2013;38(3): 
219–224.
 13. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort 
profile: the epidemiology of chronic diseases and multimorbidity. The 
EpiChron Cohort Study. Int J Epidemiol. 2018;47(2):382f–384f.
 14. WHO Collaborating Centre for Drug Statistics Methodology and the 
WHO Collaborating Centre for Drug Utilization Research and Clinical 
Pharmacological Services. Introduction to Drug Utilization Research. 
World Health Organization; 2003. Available from: http://apps.who.int/
medicinedocs/pdf/s4876e/s4876e.pdf. Accessed November 13, 2017.
 15. Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of 
adherence to diabetes medications: findings from a large pharmacy 
claims database. Diabetes Care. 2015;38(4):604–609.
 16. Malo S, Aguilar-Palacio I, Feja C, et al. Different approaches to the 
assessment of adherence and persistence with cardiovascular-disease 
preventive medications. Curr Med Res Opin. 2017;33(7):1329–1336.
 17. O’Shea MP, Teeling M, Bennett K. An observational study examining 
the effect of comorbidity on the rates of persistence and adherence to 
newly initiated oral anti-hyperglycaemic agents. Pharmacoepidemiol 
Drug Saf. 2013;22(12):1336–1344.
 18. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persis-




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





 19. Haynes RB. A critical review of the “determinants” of patient compli-
ance with therapeutic regimens. In: Sackett DL, Haynes RB, editors. 
Compliance with Therapeutic Regimens. Baltimore, MD: Johns Hopkins 
University Press; 1976;26–39.
 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin 
Trials. 1986;7(3):177–188.
 21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring incon-
sistency in meta-analyses. BMJ. 2003;327(7414):557–560.
 22. Menditto E, Guerriero F, Orlando V, et al. Self-assessment of adherence 
to medication: a case study in Campania region community-dwelling 
population. J Aging Res. 2015;2015:682503.
 23. Napolitano F, Napolitano P, Angelillo IF. Medication adherence among 
patients with chronic conditions in Italy. Eur J Public Health. 2016; 
26(1):48–52.
 24. Cahir C, Fahey T, Teljeur C, Bennett K. Medication taking behaviour 
and adverse health outcomes in community dwelling older patients. 
ISPE conference presentation, Dublin; 2016.
 25. Malo S, Aguilar-Palacio I, Feja C, et al. Persistence with Statins in 
Primary Prevention of Cardiovascular Disease: Findings From a Cohort 
of Spanish Workers. Rev Esp Cardiol (Engl Ed). 2018;71(1):26–32.
 26. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. 
Long-term persistence in use of statin therapy in elderly patients. JAMA. 
2002;288(4):455–461.
 27. Casula M, Catapano AL, Piccinelli R, et al. Assessment and potential 
determinants of compliance and persistence to antiosteoporosis therapy 
in Italy. Am J Manag Care. 2014;20(5):e138–e145.
 28. Iolascon G, Gimigliano F, Orlando V, Capaldo A, Di Somma C, Menditto E. 
Osteoporosis drugs in real-world clinical practice: an analysis of 
persistence. Aging Clin Exp Res. 2013;25(Suppl 1):S137–S141.
 29. Walker EA, Molitch M, Kramer MK, et al. Adherence to preventive 
medications: predictors and outcomes in the Diabetes Prevention Pro-
gram. Diabetes Care. 2006;29(9):1997–2002.
 30. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug 
therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17(11): 
1645–1652.
 31. Iolascon G, Gimigliano F, Moretti A, et al. Rates and reasons for 
lack of persistence with anti-osteoporotic drugs: analysis of the Cam-
pania region database. Clin Cases Miner Bone Metab. 2016;13(2): 
126–129.
 32. Scala D, Menditto E, Armellino MF, et al. Italian translation and cul-
tural adaptation of the communication assessment tool in an outpatient 
surgical clinic. BMC Health Serv Res. 2016;101(4):679–686.
 33. Coretti S, Romano F, Orlando V, et al. Economic evaluation of screen-
ing programs for hepatitis C virus infection: evidence from literature. 
Risk Manag Healthc Policy. 2015;8:45–54.
 34. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence 
and persistence across 6 chronic medication classes. J Manag Care 
Pharm. 2009;15(9):728–740.
 35. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug 
adherence rates among patients with seven different medical conditions. 
Pharmacotherapy. 2008;28(4):437–443.
 36. Larsen J, Stovring H, Kragstrup J, Hansen DG. Can differences in 
medical drug compliance between European countries be explained by 
social factors: analyses based on data from the European Social Survey, 
round 2. BMC Public Health. 2009;9:145.
 37. Kardas P. Patient compliance with antibiotic treatment for respiratory 
tract infections. J Antimicrob Chemother. 2002;49(6):897–903.
 38. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adher-
ence: a review of systematic reviews. Front Pharmacol. 2013;4:91.
 39. France G, Taroni F, Donatini A. The Italian health-care system. Health 
Econ. 2005;14(Suppl 1):S187–S202.
 40. Atella V, Kopinska JA. The impact of cost-sharing schemes on drug 
compliance in Italy: evidence based on quantile regression. Int J Public 
Health. 2014;59(2):329–339.
 41. Menditto E, Orlando V, Coretti S, et al. Doctors commitment and long-
term effectiveness for cost containment policies: lesson learned from 
biosimilar drugs. Clinicoecon Outcomes Res. 2015;11(7):575–581.
 42. Estrategia en Diabetes del Sistema. Nacional de Salud. Actualización. 
SANIDAD 2012. Ministerio de Sanidad, Servicios Sociales e Igualdad. 
Available from: http://www.msps.es/organizacion/sns/planCalidadSNS/
pdf/excelencia/cuidadospaliativos-diabetes/DIABETES/Estrategia_en_
diabetes_del_SNS_Accesible.pdf. Accessed November 10, 2017.
 43. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to 
medication adherence in the elderly: looking beyond cost and regimen 
complexity. Am J Geriatr Pharmacother. 2011;9(1):11–23.
 44. Ishisaka DY, Jukes T, Romanelli RJ, Wong KS, Schiro TA. Dispari-
ties in adherence to and persistence with antihypertensive regimens: 
an exploratory analysis from a community-based provider network. 
J Am Soc Hypertens. 2012;6(3):201–209.
 45. Sharma KP, Taylor TN. Pharmacy effect on adherence to antidiabetic 
medications. Med Care. 2012;50(8):685–691.
 46. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects 
of prescription drug copayments on statin adherence. Am J Manag 
Care. 2006;12(9):509–517.
 47. Insel K, Morrow D, Brewer B, Figueredo A. Executive function, work-
ing memory, and medication adherence among older adults. J Gerontol 
B Psychol Sci Soc Sci. 2006;61(2):P102–P107.
 48. Hugtenburg JG, Blom AT, Kisoensingh SU. Initial phase of chronic 
medication use; patients’ reasons for discontinuation. Br J Clin 
Pharmacol. 2006;61(3):352–354.
 49.  Bousquet J, Bewick M, Cano A, et al. Building bridges for innovation 
in ageing: synergies between action groups of the EIP on AHA. J Nutr 
Health Aging. 2017;21(1):92–104.
 50. Illario M, Vollenbroek-Hutten MM, Molloy DW, et al. Active and 
healthy ageing and independent living 2016. J Aging Res. 2016;2016: 
8062079.
 51. Ministry of Health. Italian Medicines Agency. Circolare AIFA del 
3 agosto 2007. Available from: http://xoomer.virgilio.it/pgiuff/
osservazionali.pdf. Accessed May 2017.
 52. Sinnott SJ, Bennett K, Cahir C. Pharmacoepidemiology resources in 





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1








patients aged >65 years
137,033
Incident users
considered in the analysis
2,639
Incident users with only 1







patients aged >65 years
500,115
Incident users
considered in the analysis
5,708
Incident users with only 1







patients aged >65 years
535,293
Incident users
considered in the analysis
16,798
Incident users with only 1








patients aged >65 years
137,033
Incident users
considered in the analysis
730
Incident users with only 1







patients aged >65 years
500,115
Incident users
considered in the analysis
1,837
Incident users with only 1







patients aged >65 years
535,293
Incident users
considered in the analysis
4,482
Incident users with only 1










































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Table S1 nonadherence rates (MPr ,80%), in all three drug classes, by age groups and by country
MPR ,80% (95% CI)
Republic of Ireland Aragon (Spain) Campania (Italy)
Antiosteoporotics
Age (in years), n
65–74 57.32 (55.4–59.23) 50 (46.6–53.4) 70.41 (65.62–74.89)
75–84 61.62 (58.91–64.28) 52.85 (49.3–56.38) 71.53 (65.87–76.73)
$85 63.31 (59.26–67.22) 61.58 (54.26–68.53) 82.46 (70.09–91.25)
Oral antidiabetics
Age (in years), n
65–74 25.87 (24.14–27.66) 27.67 (24.95–30.53) 34.39 (31.01–37.89)
75–84 28.59 (25.28–32.09) 26.58 (23.94–29.36) 38.58 (33.75–43.58)
$85 42.18 (35.43–49.15) 30.56 (25.69–35.79) 49.32 (37.4–61.28)
Antihyperlipidemics
Age (in years), n
65–74 32.64 (31.8–33.49) 54.87 (53.04–56.69) 65.83 (63.42–68.19)
75–84 38.04 (36.49–39.6) 55.92 (53.84–57.98) 67.29 (64.14–70.32)
$85 44.66 (41.74–47.61) 59.1 (54.88–63.22) 73.94 (66.54–80.45)
Abbreviation: MPr, medication possession ratio.
Figure S1 number of subjects excluded from the analysis according to selection criteria.
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Adherence to chronic medication in older populations
Table S2 non-persistence rates, in all three drug classes, by age groups and by country
Non-persistence rates (95% CI)
Republic of Ireland Aragon (Spain) Campania (Italy)
Antiosteoporotics
Age (in years), n
65–74 44.1 (42.18–46.03) 58.16 (54.78–61.48) 73.47 (68.8–77.78)
75–84 46.25 (43.51–49.01) 57.79 (54.26–61.27) 74.38 (68.85–79.38)
$85 53.07 (48.94–57.17) 68.42 (61.3–74.96) 78.95 (66.11–88.62)
Oral antidiabetics
Age (in years), n
65–74 37.31 (35.39–39.26) 46.32 (43.22–49.44) 53.89 (50.27–57.48)
75–84 32.72 (29.26–36.32) 50.61 (47.56–53.67) 53.05 (47.98–58.06)
$85 45.02 (38.19–52) 58.46 (52.99–63.77) 61.64 (49.52–72.79)
Antihyperlipidemics
Age (in years), n
65–74 35.81 (34.94–36.68) 60.1 (58.3–61.89) 67.69 (65.31–70.01)
75–84 37.38 (35.84–38.94) 61.34 (59.29–63.36) 68.6 (65.48–71.6)
$85 46.25 (43.31–49.2) 63.6 (59.45–67.61) 74.55 (67.19–81)




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
